IP Library Granted Patent US 9,670,463
Granted Patent B2
US 9,670,463 · App. 14/351,717 · Granted Jun 6, 2017

Inhibition and enhancement of reprogramming by chromatin modifying enzymes

Inventors: Tamer T. Onder (Cambridge, MA); George Q. Daley (Weston, MA)
Assignee: Children's Medical Center Corporation
C12N5/0696C12N2501/065
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,670,463
App. No.
14/351,717
Granted
Jun 6, 2017
Kind
B2
Abstract

Methods and compositions are provided for the production of stem cells and induced pluripotent stem cells, and for uses thereof.

Claims (15)

1. A method of producing induced pluripotent stem cells, the method comprising

inhibiting Dot1L in a differentiated cell and culturing the differentiated cell under reprogramming conditions to produce induced pluripotent stem cells,

wherein the reprogramming conditions comprise a reprogramming cocktail comprising a transcription factor, and

wherein the reprogramming cocktail does not include Klf4 or c-Myc.

2. The method of claim 1 , wherein Dot1L is inhibited when the cell is cultured with the reprogramming cocktail.

3. The method of claim 1 , wherein the differentiated cell is a fibroblast.

4. The method of claim 1 , wherein inhibiting Dot1L comprises inhibiting the methyltransferase activity of Dot1L.

5. The method of claim 1 , wherein Dot1L is inhibited by contacting the differentiated cell with a composition comprising a compound of formula I, I, II, or IV.

6. The method of claim 1 , wherein Dot1L is inhibited by contacting the differentiated cell with a composition comprising a compound of formula:

7. The method of claim 1 , wherein Dot1L is inhibited by contacting the differentiated cell with an shRNA that knocks down Dot1L expression.

8. The method of claim 1 , wherein the reprogramming cocktail comprises Oct4 and Sox2.

9. The method of claim 1 , wherein the reprogramming cocktail consists essentially of Oct4 and Sox2.

10. A method of producing induced pluripotent stem cells, the method comprising

inhibiting SUV39H1 in a differentiated cell and culturing the differentiated cell under reprogramming conditions to produce induced pluripotent stem cells,

wherein the reprogramming conditions comprise a reprogramming cocktail that does not include Klf4 or c-Myc.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2015
From: ONDER, TAMER T.; DALEY, GEORGE Q.
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 036723/0745 →
Continuity (2)
Provisional Application 61547404 · Oct 14, 2011
Related Publication 20140242046A1 · Aug 28, 2014